SMX Touts Oil & Gas Traceability Amid Persistent Financial Struggles

What happened

SMX issued a press release on March 13, 2026, promoting its molecular traceability technology for verifying oil and gas supply chains in response to geopolitical and regulatory pressures. However, the DeepValue report highlights that SMX has reported zero revenue through FY24 and mid-2025, with accumulated losses of $82 million and going-concern warnings. The company's survival relies on serial dilutive financings, including a $116.5 million equity facility, and multiple reverse splits to maintain Nasdaq listing. This expansion into oil and gas mirrors unproven pilots in textiles and metals that have not yet generated commercial sales. Investors should view this announcement as promotional noise, given the lack of financial progress and high risk of further dilution.

Implication

First, SMX's focus on oil and gas aligns with regulatory trends but fails to address its core issue of zero revenue and persistent cash burn. Second, historical pilots in other verticals have demonstrated technical feasibility without commercial conversion, suggesting similar outcomes here. Third, the company's reliance on dilutive equity raises, including a $116.5 million facility, increases the likelihood of shareholder value erosion. Fourth, without evidence of revenue growth, SMX's stock remains a binary bet on adoption, with high downside risk from dilution and listing issues. Fifth, investors should await hard data from filings, such as recognized revenue and share count stability, before reassessing the investment case.

Thesis delta

The news of SMX targeting oil and gas supply chains does not shift the bearish investment thesis. It represents another unproven vertical in a portfolio of pilots that have yet to generate revenue, failing to mitigate the company's financial distress. The STRONG SELL rating remains justified, with risks of further dilution and potential insolvency unchanged.